Zaid Fadul, MD, FS, FAAFP, joins for part 2 to discuss what greater adoption of AI across health care ecosystems might mean for pharmacists, patients, and more.
|Articles|February 6, 2006
FDA gives green light to anti-hepatitis B product
Advertisement
Cangene, one of Canada's largest biotechnology companies, announced that the FDA has approved HepaGam B for treatment following acute exposure to hepatitis B virus. HepaGam B is Cangene's hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus.
Advertisement
Related to this article
For pharmacies competing with CVS and relying on Caremark to serve patients, the prospect of those businesses operating under separate ownership is significant.
Erin Albert of Mark Cuban Cost Plus Drugs explains how the Team Cuban Card offers transparent pricing and fair pay for independent pharmacies.
An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.
Matthew Crawford, PhD, of the University of Virginia, and Mario Danek of Qnovia explain what pharmacists can do now and what may come next.
The inquiry puts audit practices, including how pharmacies are selected for audit, proportionality, and pharmacy advocacy in focus.
Nolla Derm’s overseeing physician, Zaid Fadul, MD, FS, FAAFP, discusses the revolutionary AI technology that could transform how health care conducts prescribing practices.
As COVID-19 vaccine guidance shifts, new data suggest vaccinated patients face no greater clot or death risk than with other respiratory infections.
Advertisement
Advertisement
Trending on Drug Topics
1
CVS Plans to Split Off Its Retail Pharmacies, Keeping Specialty Operations
2
PBM Audit Practices Under Scrutiny: What the House Inquiry Means for Independent Pharmacies
3
GLP-1s Outperform Metformin in Prediabetes Risk, MACE
4
Team Cuban Card Includes Transparent Pricing for Cash Patients
5